The results of the EVOKE and EVOKE+ trials were comprehensive in showing oral semaglutide’s lack of clinical efficacy for cognition or function in patients with early Alzheimer’s.

Anavex Life Sciences Corp. AVXL on Friday announced that a new peer-reviewed study published by the University of California in Proceedings of the National Academy of Sciences, Nexus supports the ...

Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the ...

Alzheimer's disease affects millions of people worldwide, yet the illness is hardest to catch at the very beginning, when new treatments may work best. In a new study, Duke Health researchers show ...

(Microgen Images/Science Photo Library/Getty Images) Problems with sleep often show up much earlier than more recognizable ...

Frontotemporal dementia (FTD), in particular, may be at play, and identifying ways to slow down its progression can help. In ...

Common early signs of Alzheimer’s include forgetting recent conversations, experiencing difficulty concentrating, and struggling to find the right words (Alamy/PA) A quick, three-minute brainwave test ...

Changes to tiny structures in the brain that can be detected in MRI scans could serve as a potential early indicator of Alzheimer’s, a new study suggests. Alzheimer’s dementia progressively worsens as ...

A team of researchers at the USC Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI) at the Keck School of Medicine of USC has identified important differences in how early ...

A recent study suggests that brain wave patterns during sleep can predict the speed of brain aging and potential risk of ...

Neuroscientists at King's College London have pinpointed a mechanism behind the increased neural connectivity observed in the very early stages of Alzheimer's disease. Published in Translational ...